“Another misconception is that therapy always has to involve dramatic breakthroughs,” Varma said. “Sometimes the work is ...

BioLife Solutions, Inc. (NASDAQ:BLFS) Q4 2025 Earnings Call Transcript February 26, 2026 BioLife Solutions, Inc. beats ...

The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant ...

Therapy is often framed as a solution to difficult emotions and experiences. It’s a place to talk, process and start to feel better. But simply booking an appointment and showing up doesn’t ...

DESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing ...

Good afternoon, and thank you for joining us for BioLife Solutions, Inc.'s fourth quarter and full year 2025 conference call.

Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology-focused biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announces clinical data ...

FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience ConferencePresentation will highlight lead clinical candidate FMP374, a novel dual-acting ...

Despite the growing burden of kidney disease, a complex array of issues in the US and worldwide makes innovation in the space particularly difficult.

Market Research Intellect The Financial Wellness Benefits Market is primarily driven by growing employer recognition that employee financial stress directly impacts productivity, retention, and ...

Market valued at $1.68B in 2024, projected to reach $4.58B by 2033 at 13.4% CAGR, driven by chronic wound prevalence ...

CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.